2023 Form 5500 filing — Aligos Therapeutics, Inc. 401(K) Plan

Plain-English filing summary

According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20240725151118NAL0009396323001) for Aligos Therapeutics, Inc. 401(K) Plan, reported by Aligos Therapeutics, Inc. under EIN 82-4724808 and plan number 001. It reports 88 participants. Attached schedules in the loaded dataset include Schedule I (small plan financials).

Form 5500 2 · 2023

Filing snapshot

Net assets (EOY)$10.2MReported net assets$10,194,974
Participants88
Provider compensationNone reported
Schedules filedSchedule ILoaded schedules
EFAST2 acknowledgement
20240725151118NAL0009396323001
Plan sponsor
Aligos Therapeutics, Inc.
EIN
82-4724808
Plan number
001
Location
South San Francisco, CA
Received date
not reported in the loaded dataset
How to read this filing
  • This is a single annual Form 5500 filing, identified by its EFAST2 acknowledgement id.
  • Schedule chips (Sch H / I / C) show which schedules this filing includes.
  • Net assets = total assets minus total liabilities (Schedule H/I).
  • Fields a filing did not report are labeled not reported in the loaded dataset — never estimated.
  • For the plan's full history, open the plan profile.
Schedule I · 2023

Reported financial snapshot

Reported figures as filed, in whole dollars. Only fields the filing reports are shown.

Reported balance (end of year)$10.2M total assets
Net assets$10.2MLiabilities$0
Money in vs. money out
Total income / additions$4.5M
Total expenses$1.1M
Benefits paid / distributions$1.2M
Contributions
Employer$774.8K
Participant$1.5M
Full reported line items
Total assets (EOY)
$10,194,974
Total liabilities (EOY)
$0
Net assets (EOY)
$10,194,974
Employer contributions
$774,847
Participant contributions
$1,507,756
Total income / additions
$4,464,762
Benefits paid
$1,154,554
Administrative expenses
$1,274
Total expenses
$1,134,557
Net increase / (decrease)
$3,330,205

What to inspect next

Frequently asked questions

What does EFAST2 acknowledgement 20240725151118NAL0009396323001 cover?
It is the 2023 Form 5500 filing for Aligos Therapeutics, Inc. 401(K) Plan, reported by Aligos Therapeutics, Inc. (EIN 82-4724808).
Which Form 5500 schedules are attached to this 2023 filing?
Attached schedules in the loaded dataset include Schedule I (small plan financials).

Related Form 5500 pages